Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

Anti-melanoma differentiation-associated protein 5 (MDA5)-positive rapidly progressive interstitial lung disease (RP-ILD) is associated with poor prognosis, and the most effective therapeutic intervention has not been established. Herein we report a case of a 45-year-old female patient who presented...

Full description

Bibliographic Details
Main Authors: Tsai-Hung Yen, Chih-Wei Tseng, Kao-Lun Wang, Pin-Kuei Fu
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Medicina
Subjects:
MDA-5
RP-ILD
rituximab
tofacitinib
pirfenidone
Online Access:https://www.mdpi.com/1648-9144/57/12/1358

Internet

https://www.mdpi.com/1648-9144/57/12/1358

Similar Items